Abstract
There is a need for human immunodeficiency virus (HIV) screening assays which will distinguish uninfected HIV vaccine recipients from HIV-infected individuals. Commercial screening kits were used to test serum samples from low- and high-risk participants in clinical trials before and after immunization with various recombinant HIV type 1 (HIV-1) envelope glycoprotein 120 (gp120) candidate vaccines. All kits were 100% sensitive in detecting HIV infection. Both Murex Single Use Diagnostic System and United Biomedical, Inc., HIV type 1 or 2 (HIV-1/2) enzyme immunoassay (EIA) kits, which detect antibodies to HIV-1 gp41, were 98 to 100% specific when used to screen baseline or recombinant gp120-vaccinated populations as vaccine-induced antibodies to gp120 were nonreactive in these tests. The Abbott HIVAB HIV-1 EIA (lysate of whole infected cells, reactive with anti-gp120 antibodies) gave high levels of reactivity due to vaccine-induced antibodies and a high baseline rate of false positives (12 of 83) among nonvaccinated high-risk volunteers. Assays containing only gp41 and p24 solid-phase components are compatible with gp120-based vaccines but are unlikely to be useful in a similar role for vaccines containing gp160, gp41, or gp120 plus p24 antigens. Efficacy trials must be designed in concert with available diagnostic screening assays to avoid problems caused by vaccine-induced seroconversion in high-risk populations.
Full Text
The Full Text of this article is available as a PDF (166.4 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alter H. J., Epstein J. S., Swenson S. G., VanRaden M. J., Ward J. W., Kaslow R. A., Menitove J. E., Klein H. G., Sandler S. G., Sayers M. H. Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors--an assessment of the efficacy of testing in donor screening. The HIV-Antigen Study Group. N Engl J Med. 1990 Nov 8;323(19):1312–1317. doi: 10.1056/NEJM199011083231905. [DOI] [PubMed] [Google Scholar]
- Behets F., Disasi A., Ryder R. W., Bishagara K., Piot P., Kashamuka M., Kamenga M., Nzila N., Laga M., Vercauteren G. Comparison of five commercial enzyme-linked immunosorbent assays and Western immunoblotting for human immunodeficiency virus antibody detection in serum samples from Central Africa. J Clin Microbiol. 1991 Oct;29(10):2280–2284. doi: 10.1128/jcm.29.10.2280-2284.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Berman P. W., Gregory T. J., Riddle L., Nakamura G. R., Champe M. A., Porter J. P., Wurm F. M., Hershberg R. D., Cobb E. K., Eichberg J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature. 1990 Jun 14;345(6276):622–625. doi: 10.1038/345622a0. [DOI] [PubMed] [Google Scholar]
- Busch M. P., Taylor P. E., Lenes B. A., Kleinman S. H., Stuart M., Stevens C. E., Tomasulo P. A., Allain J. P., Hollingsworth C. G., Mosley J. W. Screening of selected male blood donors for p24 antigen of human immunodeficiency virus type 1. The Transfusion Safety Study Group. N Engl J Med. 1990 Nov 8;323(19):1308–1312. doi: 10.1056/NEJM199011083231904. [DOI] [PubMed] [Google Scholar]
- Genesca J., Shih J. W., Jett B. W., Hewlett I. K., Epstein J. S., Alter H. J. What do western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? Lancet. 1989 Oct 28;2(8670):1023–1025. doi: 10.1016/s0140-6736(89)91027-1. [DOI] [PubMed] [Google Scholar]
- Johnson B. K., Stone G. A., Godec M. S., Asher D. M., Gajdusek D. C., Gibbs C. J., Jr Long-term observations of human immunodeficiency virus-infected chimpanzees. AIDS Res Hum Retroviruses. 1993 Apr;9(4):375–378. doi: 10.1089/aid.1993.9.375. [DOI] [PubMed] [Google Scholar]
- Johnson J. E. Detection of human immunodeficiency virus type 1 antibody by using commercially available whole-cell viral lysate, synthetic peptide, and recombinant protein enzyme immunoassay systems. J Clin Microbiol. 1992 Jan;30(1):216–218. doi: 10.1128/jcm.30.1.216-218.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lee T. H., el-Amad Z., Reis M., Adams M., Donegan E. A., O'Brien T. R., Moss A. R., Busch M. P. Absence of HIV-1 DNA in high-risk seronegative individuals using high-input polymerase chain reaction. AIDS. 1991 Oct;5(10):1201–1207. doi: 10.1097/00002030-199110000-00008. [DOI] [PubMed] [Google Scholar]
- Midthun K., Garrison L., Clements M. L., Farzadegan H., Fernie B., Quinn T. Frequency of indeterminate western blot tests in healthy adults at low risk for human immunodeficiency virus infection. The NIAID AIDS Vaccine Clinical Trails Network. J Infect Dis. 1990 Dec;162(6):1379–1382. doi: 10.1093/infdis/162.6.1379. [DOI] [PubMed] [Google Scholar]
- Schechter M. T., Neumann P. W., Weaver M. S., Montaner J. S., Cassol S. A., Le T. N., Craib K. J., O'Shaughnessy M. V. Low HIV-1 proviral DNA burden detected by negative polymerase chain reaction in seropositive individuals correlates with slower disease progression. AIDS. 1991 Apr;5(4):373–379. doi: 10.1097/00002030-199104000-00003. [DOI] [PubMed] [Google Scholar]
- Schwartz D. H., Gorse G., Clements M. L., Belshe R., Izu A., Duliege A. M., Berman P., Twaddell T., Stablein D., Sposto R. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet. 1993 Jul 10;342(8863):69–73. doi: 10.1016/0140-6736(93)91283-r. [DOI] [PubMed] [Google Scholar]
- Tamashiro H., Maskill W., Emmanuel J., Fauquex A., Sato P., Heymann D. Reducing the cost of HIV antibody testing. Lancet. 1993 Jul 10;342(8863):87–90. doi: 10.1016/0140-6736(93)91289-x. [DOI] [PubMed] [Google Scholar]